Summary
This prediction ended on 22.04.15 with a price of €84,800,000. Massive losses of -67.18% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Neovacs | - | - | - | - |
| iShares Core DAX® | 0.760% | 1.149% | 17.258% | 65.150% |
| iShares Nasdaq 100 | 0.732% | 1.884% | 8.152% | 103.965% |
| iShares Nikkei 225® | 1.025% | -0.865% | 13.066% | 45.628% |
| iShares S&P 500 | -0.036% | 1.480% | 3.393% | 63.267% |
According to melinda what are the pros and cons of Neovacs for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Neovacs diskutieren
Biotech-
Markt Antikörper
(Laufzeit überschritten)